Actively Recruiting
Taurine Supplementation in Long COVID
Led by University of Alberta · Updated on 2026-03-16
300
Participants Needed
5
Research Sites
158 weeks
Total Duration
On this page
Sponsors
U
University of Alberta
Lead Sponsor
C
Canadian Institutes of Health Research (CIHR)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS-CoV-2 infection. This condition, known as Long COVID (LC) or sometimes referred to as Post-COVID Condition (PCC) or post-acute sequelae of COVID-19, has emerged as a complex multisystemic condition and challenging health issue, affecting approximately 10% of COVID-19 patients. Various symptoms characterize LC, including fatigue, sleep disturbances, cognitive impairment, and mood disturbances. Some of the symptoms are shared with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - a condition marked by debilitating fatigue and a host of other symptoms without precise biomarkers or objective tests for diagnosis. Effective LC treatments remain elusive and LC patients continue to grapple with persistent symptoms that significantly impact their quality of life. Given the lack of effective treatments, it is imperative to explore novel therapeutic approaches that may alleviate the suffering of this patient population.
CONDITIONS
Official Title
Taurine Supplementation in Long COVID
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Positive COVID-19 test by RT-PCR, antibody, or antigen at least 3 months before randomization, or diagnosed with COVID-19 by investigator after October 15, 2019
- Stable treatment regimen for any treatable symptoms for at least 4 weeks prior to study entry
- Lingering COVID-19 symptoms lasting at least 2 months beyond 3 months from onset
- Symptoms present at the time of randomization
- Sexually active individuals of childbearing potential must agree to use effective contraception or true abstinence during treatment
- Ability to provide informed consent and comply with study requirements
- Discontinued medications for fatigue or cognition (like sildenafil, modafinil, armodafinil, guanfacine, N-acetyl cysteine, ADHD stimulants) for at least 4 weeks before enrollment
You will not qualify if you...
- History of mechanical ventilation or extracorporeal membrane oxygen (ECMO) for COVID-19
- Current end-organ failure, organ transplant, or hospitalization in acute care
- Contraindications to the study treatment
- Currently taking the study intervention
- Participation in another interventional trial (observational studies allowed)
- Currently pregnant or breastfeeding
- Enrolled in another clinical trial targeting neurocognitive symptoms in Long COVID
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
University of Alberta Hospital, Kaye Edmonton Clinic
Edmonton, Alberta, Canada, T6G 2B7
Actively Recruiting
2
BC Women's Hospital
Vancouver, British Columbia, Canada, V6H 3N1
Not Yet Recruiting
3
University Health Network
Toronto, Ontario, Canada
Actively Recruiting
4
Institut de recherches cliniques de Montréal
Montreal, Quebec, Canada
Not Yet Recruiting
5
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke
Sherbrooke, Quebec, Canada
Not Yet Recruiting
Research Team
L
Lawrence Richer, MD, MSc
CONTACT
E
Ellen Morrison, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here